Early human intervention

Clinical evaluation of changes in biomarkers by oral intake of NMN

Yuji Morita, Hiromi Izawa, Atsuyuki Hirano, Eriko Mayumi, Seigo Isozaki, Yoshikazu Yonei

Glycative Stress Research · 2022 · 9(2):33–41

Original publication

Study at a glance

Design: Single-arm, open-label, pre-post intervention study; 8 weeks
Population or model: Postmenopausal women without underlying disease; mean age 55 years
Sample size: 17 enrolled; 16 completed after one withdrawal for persistent mild headache
Intervention: Pure NMN 300 mg/day orally for 8 weeks
Publication type: Single-arm intervention study
Evidence class: human-study
Research area: Exploratory biomarker and subjective measures
Trial registration: Not stated in publication.

Study endpoints

Body measurements and basal metabolic rate
Blood pressure and grip strength
Glycation autofluorescence
Blood chemistry and hormones
Blood SIRT1 mRNA, NMN, NAD and nicotinamide
Immune-cell subsets
Skin, sleep, fatigue and other subjective diary measures

Plain-language summary

This exploratory single-arm study gave 300 mg/day NMN to 17 postmenopausal women for eight weeks and compared biomarkers before and after supplementation. Sixteen participants completed the study.

Several laboratory, metabolic, immune, glycation, and subjective measures changed over time, including NAD-related metabolites. One participant withdrew after persistent mild headache.

Because there was no placebo or untreated control group and many endpoints were tested, the study cannot establish that NMN caused the observed changes. It is best treated as early human exploratory evidence.

Key findings

Nicotinamide and NAD-related measures changed over the eight-week intervention.
The report described statistically significant changes in adiponectin, BMI, glycation autofluorescence, HbA1c, HDL-C and several other biomarkers.
Participants reported subjective changes in skin, sleep and fatigue measures.
One of 17 participants discontinued at four weeks because of persistent mild headache.
No major laboratory safety problem was reported among the 16 completers.

Limitations

No placebo or untreated comparator was included.
Small sample of postmenopausal women only.
Many biomarkers and subjective endpoints were tested, increasing multiplicity concerns.
One participant withdrew because of persistent mild headache.
Funding, competing-interest and trial-registration statements were not stated in the publication information verified for this record.

Funding and transparency

Funding

Not stated in publication.

Competing interests

Not stated in publication.

HealthspanX observation

This study is useful for hypothesis generation but should not be treated as confirmatory because it lacks a comparator and evaluates many endpoints.

Interpretive weight

Limited

Small uncontrolled before-and-after study with numerous biomarkers and subjective endpoints; causal treatment effects cannot be separated from time or other influences.

This record summarizes a publication; it is not medical advice or a claim that a HealthspanX product reproduces the study's results. Report a correction.

Explore HealthspanX

Science

Your wellbeing